Totals of 400 chronic hepatitis B or non-alcoholic fatty liver disease (NAFLD) patients with or without cirrhosis will be enrolled. Patients' clinical characteristics, including alanine aminotransferase, aspartic aminotransferase, total bilirubin, direct bilirubin, indirect bilirubin, triglyceride and total cholesterol, hepatitis B surface antigen, steatosis, and liver stiffness measurement will be collected. The consistence of liver fibrosis and steatosis assessment between Hepatus and FibroScan will be evaluated in this study.
Study Type
OBSERVATIONAL
Enrollment
400
Yameng Sun
Beijing, Select A State Or Province, China
RECRUITINGConsistency of liver stiffness and steatosis results in the same location between Hepatus in continuous measurement mode and FibroScan in single detection mode.
Consistency of liver stiffness and steatosis between Hepatus and FibroScan.
Time frame: 1 to 3 years
Consistency of liver stiffness and steatosis results between Hepatus in continuous measurement mode and FibroScan in single detection mode through the respective localization methods.
The localization method of Hepatus is the real-time two-dimensional image guiding system, which is manually location in FibroScan.
Time frame: 1 to 3 years
Consistency of liver stiffness and steatosis results between Hepatus and FibroScan in single detection mode.
The localization methods include the respective localization methods in Hepatus and FibroScan, and manually locating.
Time frame: 1 to 3 years
Comparison of measurement performance in Hepatus under continuous detection mode and in FibroScan through single detection mode.
Evaluation of measurement performance includes the rate of successful detection, time taken for validated detection, stability of liver stiffness measurement and controlled attenuation parameter.
Time frame: 1 to 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.